Posted by Michael Wonder on 01 Nov 2022
Association between US drug price and measures of efficacy for oncology drugs approved by the US FDA from 2015 to 2020
31 October 2022 - The past five years have seen a marked increase in the number of cancer therapies on the market and a greater interest in value-based pricing.
It is unclear whether the value proposition has shifted: have cancer drugs started to rely on improved benefit and decreased use of surrogate end points to justify skyrocketing costs?
We described these trends by estimating all US FDA anti-cancer approvals in recent years and evaluating if an association exists between their cost and efficacy.
